ESC 365 - Exploring the latest evidence of cardiovascular benefits with glucagon-like peptide 1 receptor agonists

Open Access

Exploring the latest evidence of cardiovascular benefits with glucagon-like peptide 1 receptor agonists

Event: ESC Congress 2021 - The Digital Experience

Topic: Risk Factors and Prevention

Session type: Satellite Symposium

Sponsored by Novo Nordisk A/S

Date: 27 August 2021

Time: 13:00 - 13:45

Congress Session

This content is currently on OPEN ACCESS

Sign in to view the resources

4 presentations in this session

Glucagon-like peptide 1 receptor agonists & cardiovascular outcomes: What have we learned?

Speaker: Doctor M. Cavender (Chapel Hill, US)

Cardiovascular effects of glucagon-like peptide 1 receptor agonists.

Speaker: Doctor M. Husain (Toronto, CA)

Glucagon-like peptide 1 receptor agonist use in cardiology.

Speaker: Professor M. Petrie (Glasgow, GB)

Live panel discussion.

3 speakers from this session

Doctor Matthew Cavender

University of North Carolina Hospitals, Chapel Hill (United States of America)

5 presentations

0 follower

Doctor Mansoor Husain

University of Toronto, Toronto (Canada)

7 presentations

1 follower

Professor Mark Petrie

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

19 presentations

0 follower

This platform is supported by